Sign inJoin
Company / Finance

Achieve Life Sciences, Inc.

ACHV · NASDAQ

Achieve has late-stage cytisinicline data, an accepted smoking-cessation NDA, and a fresh financing. The catch is that management now expects a manufacturing-driven FDA Complete Response Letter before any U.S. launch.

FollowAdd to WatchlistAsk Question
NASDAQACHVCoverage BootstrapBiotechnologySpecialty PharmaceuticalsNicotine Dependence
Latest ReportMay 13, 2026Achieve Life Sciences: the quit-smoking pill with $180 million and an FDA manufacturing detourView report ->Total Reports1Published reportView all ->Active Discussions0No visible comments yetView discussions ->Member WorkspaceLockedFinancials, timeline, comparisons, scorecard, and discussion require a paid login.View access ->
Company filters1 company reports
Latest Thesis

Achieve Life Sciences: the quit-smoking pill with $180 million and an FDA manufacturing detour

Achieve has late-stage cytisinicline data, an accepted smoking-cessation NDA, and a fresh financing. The catch is that management now expects a manufacturing-driven FDA Complete Response Letter before any U.S. launch.

May 13, 2026Research reportSlides available
Read reportOpen slidesDiscussion (0)
Achieve Life Sciences, Inc.Life Sciences: the quit-smoking pill with $180 million and an FDMay 13, 2026
Member workspace

Financials and workspace tools are for paid members.

Paid login unlocks company financials, filing timeline, peer comparison, scorecard, and discussion. Valuation remains admin-only while we finalize market-data licensing.

Sign in to continue

Recent Reports

Compact report index for this company.

View all 1 reports ->
ReportTypeUpdatedReadActions
Achieve Life Sciences: the quit-smoking pill with $180 million and an FDA manufacturing detourAchieve has late-stage cytisinicline data, an accepted smoking-cessation NDA, and a fresh financing. The catch is that management now expects a manufacturing-driven FDA Complete Response Letter before any U.S. launch.NASDAQMay 13, 2026Research reportReadSlides